Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Clinical Review of KINRIX Biologics License Application: Post-marketing Study Commitment

Date: June 19, 2008

From:
Karen M. Farizo, M.D.
Medical Officer
Vaccines Clinical Trials Branch
Division of Vaccines and Related Product Applications
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research
Food and Drug Administration

Subject: Clinical Review of KINRIX Biologics License Application: Post-marketing Study Commitment

To: BLA STN# 125260

Through:
Lucia Lee, M.D.
Team Leader, Vaccines Clinical Trials Branch
Division of Vaccines and Related Products Applications
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research
Food and Drug Administration

cc:
Michael Schmitt, PhD
Joseph Temenak, PhD

The January 31, 2008 clinical review of the KINRIX Biologics License Application described the applicant's post-marketing commitment to conduct a randomized, open label, comparative trial to evaluate the immunogenicity and safety of KINRIX administered concomitantly with varicella vaccine. A control group will receive KINRIX and varicella vaccine at separate visits. Data on concomitant administration of KINRIX with varicella vaccine were not available from the pre-licensure clinical trials because the trials were conducted prior to recommendations to administer a second dose of varicella vaccine in children 4-6 years of age.

In view of the FDA Amendments Act of 2007 (FDAAA) Title IX Section 901, it is important to clarify that the proposed post-marketing clinical trial will be conducted primarily to evaluate the immunogenicity of KINRIX administered concomitantly with varicella vaccine. While trial participants will be monitored for safety post-vaccination, the primary objectives and endpoints of the trial will pertain to the immune responses following KINRIX. The trial is not being planned to assess any serious risk, signals of serious risk, or the potential for serious risk. For these reasons, the planned trial is not considered a post-marketing requirement under FDAAA.


Return to Approval History, Letters, Reviews, and Related Documents

Page Last Updated: 09/17/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.